Holen Sie sich die Stockscreener-App
1,085.19
2.07%
-22.90
Handel nachbörslich:
1086.58
1.39
+0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,108.09
Offen:
$1113.69
24-Stunden-Volumen:
3.12M
Relative Volume:
0.91
Marktkapitalisierung:
$971.27B
Einnahmen:
$59.42B
Nettoeinkommen (Verlust:
$18.41B
KGV:
53.67
EPS:
20.2197
Netto-Cashflow:
$6.44B
1W Leistung:
+0.98%
1M Leistung:
+8.78%
6M Leistung:
+39.55%
1J Leistung:
+37.85%
1-Tages-Spanne:
$1,070.15
$1,133.95
1-Wochen-Bereich:
$1,033.38
$1,133.95
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,085.19 | 991.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.75 | 499.90B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.13 | 412.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.99 | 269.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.46 | 272.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Lilly Endowment sells Eli Lilly & Co (LLY) stock worth $322m - Investing.com Canada
2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition - Law360
Eli Lilly's (LLY) Taltz and Zepbound Show Positive Results in Ps - GuruFocus
Eli Lilly (LLY) Reports Positive Results with Psoriatic Arthritis Treatment - GuruFocus
Lilly trial finds psoriatric arthritis, weight improvement in Taltz + Zepbound combo - Seeking Alpha
Eli Lilly (LLY) Poised for Aggressive M&A Amid Biopharma Surge - GuruFocus
Lilly’s taltz and zepbound combination shows efficacy in psoriatic arthritis - Investing.com
Lilly touts promise of Zepbound-Taltz combo in patients with obesity and psoriatic arthritis - Fierce Pharma
Lilly’s Zepbound Plus Arthritis Drug Taltz Eases Joint Pain - Bloomberg.com
Biopharma stocks to see increased M&A activity amid Eli Lilly-Ventyx deal (IBB:NASDAQ) - Seeking Alpha
Lilly buys Ventyx in $1.2bn deal to tackle chronic inflammation - BioXconomy
The Best Technology ETF to Invest $1,000 in Right Now - The Motley Fool
Eli Lilly stock rises as Bernstein reiterates Outperform rating By Investing.com - Investing.com Canada
Lilly to acquire Ventyx Biosciences stock for $14 per share - Investing.com
Lilly to acquire Ventyx Biosciences stock for $14 per share By Investing.com - Investing.com UK
Eli Lilly stock to acquire Ventyx for $1.2 billion, Cantor Fitzgerald maintains Overweight rating - Investing.com
ClearBridge Large Cap Growth Strategy’s Thoughts on Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn - Pharmaceutical Technology
Dow Drops, Eli Lilly Rockets — And Google Quietly Beats Apple at Its Own Game - Eudaimonia and Co
Eli Lilly completes billion-dollar acquisition of US biotech company - medwatch.com
Eli Lilly to acquire Ventyx Biosciences stock for $1.2 billion as Clear Street downgrades - Investing.com
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition - Investing.com UK
Eli Lilly Shares Surge on Strategic Expansion in Metabolic Therapeutics - AD HOC NEWS
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion - GuruFocus
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Lilly inks $950M deal to develop bi- and tri-specifics with InduPro - FirstWord
Ventyx Biosciences Upon Termination Of Merger Under Specified Circumstances, Co Will Be Required To Pay Eli Lilly Termination Fee Of $44 Million - TradingView — Track All Markets
Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy - Reuters
Eli Lilly & Co (LLY) Receives a New Rating from Jefferies - The Globe and Mail
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus - TechStock²
Eli Lilly (LLY) Set to Acquire Ventyx Biosciences in Cash Deal - GuruFocus
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - PR Newswire
InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecif - PharmiWeb.com
Eli Lilly Joins Trump Program Expanding Obesity Drug Access - Bloomberg Law News
Eli Lilly (LLY) Partners with InduPro for Oncology Innovations - GuruFocus
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal - Stocktwits
InduPro, Inc. Announces Strategic Collaboration with Eli Lilly and Company to Develop First-In-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro?s Proximity-Guided Platform - MarketScreener
Lilly to work with InduPro on developing oncology therapies in up to $950M deal - Seeking Alpha
Eli Lilly and Regencell among market cap stock movers on Wednesday - Investing.com
Aktis Oncology upsizes IPO by 50%, attracts $100 million from Eli Lilly - Investing.com
Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition - Benzinga
Lilly in talks to buy Ventyx Biosciences for more than $1B, WSJ reports - Indianapolis Business Journal
Aktis Oncology secures Lilly as anchor investor for upsized US IPO - Reuters
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Finviz
The Truth About Eli Lilly and Co: Is Wall Street’s Favorite Drug Stock Still Worth the Hype? - AD HOC NEWS
Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup - TipRanks
Eli Lilly’s Billion-Dollar Push to Lead the Obesity Drug Market - AD HOC NEWS
Eli Lilly surges ahead on raised price target - medwatch.com
Eli Lilly (LLY) Nears $1 Billion Acquisition of Ventyx Biosciences (VTYX) - GuruFocus
Eli Lilly and Intel lead market cap stock movers on Wednesday - Investing.com
Eli Lilly Set to Back Aktis Oncology’s Upsized $318 Million IPO - Bloomberg.com
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):